Related Experiment Video
Updated: Aug 8, 2026

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3
Published on: January 24, 2016
Mechanism of STAT3 activation by insulin-like growth factor I receptor
1Department of Microbiology, Mount Sinai School of Medicine, New York, New York 10029, USA. zongc01@doc.mssm.edu
Abstract:
Recent evidence indicates that STAT proteins can be activated by a variety of receptor and non-receptor protein-tyrosine kinases. Unlike cytokine-induced activation of STATs, where JAKs are known to play a pivotal role in phosphorylating STATs, the mechanism for receptor protein-tyrosine kinase-mediated activation of STATs remains elusive. In this study, we investigated the activation of STAT proteins by the insulin-like growth factor I receptor (IGF-IR) in vitro and in vivo and assessed the role of JAKs in the process of activation. We found that STAT3, but not STAT5, was activated in response to IGF-I in 293T cells cotransfected with IGF-IR and STAT expression vectors. Moreover, tyrosine phosphorylation of STAT3, JAK1, and JAK2 was increased upon IGF-I stimulation of endogenous IGF-IR in 293T cells transfected with the respective STAT or JAK expression vector. Supporting the observation in 293T cells, endogenous STAT3 was tyrosine-phosphorylated upon IGF-I stimulation in the muscle cell line C2C12 as well as in various embryonic and adult mouse organs during different stages of development. Dominant-negative JAK1 or JAK2 was able to block the IGF-IR-mediated tyrosine phosphorylation of STAT3 in 293T cells. A newly identified family of proteins called SOCS (suppressor of cytokine signaling), including SOCS1, SOCS2, SOCS3 and CIS, was able to inhibit the IGF-I-induced STAT3 activation as well with varying degrees of potency, in which SOCS1 and SOCS3 appeared to have the higher inhibitory ability. Inhibition of STAT3 activation by SOCS could be overcome by overexpression of native JAK1 and JAK2. We conclude that IGF-I/IGF-IR is able to mediate activation of STAT3 in vitro and in vivo and that JAKs are essential for the process of activation.
Insights
Insulin-like growth factor I receptor (IGF-IR) activates STAT3 protein signaling. Janus kinases (JAKs) are essential for this IGF-I-induced STAT3 activation, a process also modulated by suppressor of cytokine signaling (SOCS) proteins.
Area of Science:
- Molecular Biology
- Cell Signaling
- Signal Transduction
Background:
- STAT proteins are activated by various protein-tyrosine kinases.
- Cytokine-induced STAT activation involves Janus kinases (JAKs).
- Mechanisms of receptor protein-tyrosine kinase-mediated STAT activation are not fully understood.
Purpose of the Study:
- To investigate STAT protein activation by the insulin-like growth factor I receptor (IGF-IR).
- To elucidate the role of JAKs in IGF-IR-mediated STAT activation.
- To assess the involvement of suppressor of cytokine signaling (SOCS) proteins in this pathway.
Main Methods:
- Investigated STAT3 and STAT5 activation in 293T cells co-transfected with IGF-IR and STAT expression vectors.
- Stimulated endogenous IGF-IR in 293T cells, C2C12 muscle cells, and mouse organs with IGF-I.
- Utilized dominant-negative JAK1/JAK2 and SOCS family proteins (SOCS1-3, CIS) to assess inhibitory effects.
Main Results:
- IGF-I stimulation activated STAT3, but not STAT5, in 293T cells expressing IGF-IR.
- Tyrosine phosphorylation of STAT3, JAK1, and JAK2 increased upon IGF-I stimulation.
- Dominant-negative JAKs blocked IGF-IR-mediated STAT3 phosphorylation; SOCS proteins inhibited activation, with SOCS1 and SOCS3 being most potent.
Conclusions:
- IGF-I/IGF-IR mediates STAT3 activation both in vitro and in vivo.
- JAKs are essential for IGF-IR-induced STAT3 activation.
- SOCS proteins can inhibit IGF-I-induced STAT3 activation, with varying potencies.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Amplifying Signals via Enzymatic Cascade
The JAK-STAT Signaling Pathway
PI3K/mTOR/AKT Signaling Pathway
TGF - β Signaling Pathway
Insulin: The Receptor and Signaling Pathways

